-
Thoughts from the World Vaccine Congress, Washington 2018
- posted by: Lee Smith
- posted on: April 3, 2018
I'm currently attending the World Vaccine Congress 2018 in Washington to hear the latest musing from the sector's thought leaders and also find out about the latest technologies that are being used in the production of vaccines globally.
Read the rest of this post -
Themis Bioscience Enters into a $37.5m Agreement with CEPI to Develop a Lassa Fever and MERS-CoV Vaccine
- posted by: Lee Smith
- posted on: March 7, 2018
Themis Bioscience GmbH, an Austrian based vaccine company, has secured a $37.5m agreement with CEPI to create new vaccines for the infectious diseases Lassa Fever and MERS-CoV.
Read the rest of this post -
Chikungunya Vaccine UK Government Funding Secured By Themis Bioscience
- posted by: Lee Smith
- posted on: September 12, 2017
One year ago in September 2016 the UK's government innovation agency Innovate UK provided £1 million to help accelerate Themis' Zika candidate into the clinic. Now, a year on they are providing another £3 million for clinical trials to help propel the firm's Chikungunya vaccine forward.
Read the rest of this post -
GRA Client, Themis Bioscience Start Phase II Chikungunya Clinical Study In Endemic Area
- posted by: Lee Smith
- posted on: August 8, 2017
Themis Bioscience begins testing of their Chikungunya vaccine in Puerto Rico phase II clinical study
Read the rest of this post -
New Article: Public-Private Coalition's: High-Profile Delinkage Policy For Emerging Vaccines
- posted by: Lee Smith
- posted on: July 11, 2017
Recently I've contributed a small part in Tatum Anderson's April 2017 article Public-Private Coalition's: High-Profile Delinkage Policy For Emerging Vaccines.
Read the rest of this post -
Bioprocess International Article on Ensuring and Controlling the Quality of Biologics
- posted by: Lee Smith
- posted on: June 30, 2017
Article titled The State of the Industry as a celebration of BioProcess International’s 15th year of publication
Read the rest of this post -
Use of Design of Experiments (DOE) for Vaccine Formulation
- posted by: Lee Smith
- posted on: August 31, 2017
How DOE was used to create a new formulation for a live attenuated viral vaccine
Read the rest of this post -
Themis and Bharat Biotech to kick off new testing for Chikungunya vaccines
- posted by: Lee Smith
- posted on: June 12, 2017
Some 65 years after the Chikungunya viral disease got it’s name, two different biotech firms have started their clinical trials.
Read the rest of this post -
Takeda have finished enrolling 20,100 children for their phase 3 dengue vaccine.
- posted by: Lee Smith
- posted on: April 25, 2017
Takeda has recently finished enrolling 20,100 children for their phase 3 dengue vaccine clinical study in 8 endemic countries after just seven months. The study, that was started back in September 2016, is a placebo controlled study covering two doses of the vaccine each three months apart in children aged from 4 to 16. The aim is to confirm if the vaccine can protect against any dengue serotype of varying severities regardless of previous exposure.
Read the rest of this post